...
首页> 外文期刊>Journal of Medicinal Chemistry >Design, Synthesis, and Structure?Activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors
【24h】

Design, Synthesis, and Structure?Activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors

机译:设计,合成和结构-活性关系的吡啶并喹唑啉羧酰胺作为RNA聚合酶I抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

RNA polymerase I (Pol I) is a dedicated polymerase that transcribes the 45S ribosomal (r) RNA precursor. The 45S rRNA precursor is subsequently processed into the mature 5.8S, 18S, and 28S rRNAs and assembled into ribosomes in the nucleolus. Pol I activity is commonly deregulated in human cancers. On the basis of the discovery of lead molecule BMH-21, a series of pyridoquinazolinecarboxamides have been evaluated as inhibitors of Pol I and activators of the destruction of RPA194, the Pol I large catalytic subunit protein. Structure?activity relationships in assays of nucleolar stress and cell viability demonstrate key pharmacophores and their physicochemical properties required for potent activation of Pol I stress and cytotoxicity. This work identifies a set of bioactive compounds that potently cause RPA194 degradation that function in a tightly constrained chemical space. This work has yielded novel derivatives that contribute to the development of Pol I inhibitory cancer therapeutic strategies.
机译:RNA聚合酶I(Pol I)是一种专用的聚合酶,可转录45S核糖体(r)RNA前体。随后将45S rRNA前体加工成成熟的5.8S,18S和28S rRNA,并组装到核仁中的核糖体中。 Pol I活性在人类癌症中通常被放松。基于前导分子BMH-21的发现,已评估了一系列吡啶基喹唑啉甲酰胺作为Pol I的抑制剂和破坏RPA194(Pol I的大催化亚基蛋白)的破坏活化剂。核仁应激和细胞活力测定中的结构活性关系证明了关键药效团及其有效激活Pol I应激和细胞毒性所需的理化特性。这项工作确定了一组可能导致RPA194降解的生物活性化合物,这些化合物在严格限制的化学空间中发挥作用。这项工作产生了新的衍生物,有助于发展Pol I抑制性癌症治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号